A Urinary Fat-Mobilising Substance G. L. S. PAWAN (DEPARTMENT OF MEDICINE, MIDDLESEX HOSPITAL MEDICAL SCHOOL, LONDON, W.l) Studies on human obese subjects (Kekwick & Pawan, 1953 , 1957 Pawan 1959) suggested the existence of a mechanism for controlling the mobilisation and catabolism of depot fat in man. This mechanism appeared to be sensitive to changes in the total calorie intake as well as to the composition (particularly the carbohydrate content) of the diet. It was considered that such a mechanism should be operating at a maximum during complete fasting and that if any hormonal agent were involved it should possibly be detectable in the urine under these conditions.
Using techniques previously described (Chalmers, Pawan Pawan, 1960) it was shown that a peptide-like substance (provisionally called FMS), possibly of anterior pituitary origin, could be extracted from the urine of normal persons during fasting and that this substance was also present in the urine of human subjects in various physiological and pathological states characterised by increased fat catabolism.
Active material was also detected in the urine of the fasted horse, sheep, goat, dog and rabbit. FMS appears to differ in several respects from other hormones known to affect fat metabolism.
FMS, when injected into mice, produces a transient hypo glycaemia, hyperlipaemia, hyperketonaemia, increased mobilisation and catabolism of depot fat, and weight loss without affecting appetite. It has been shown to be active both in vivo and in vitro (Chalmers, Pawan & Kekwick, supra; Cahill, Pawan & Chalmers, 1961) . This substance may be of some biological importance in the metabolism of body fat in man.
Serum haptoglobin levels have been measured in 115 cases of liver disease (Williams, Speyer and Billing, 1961) , using the method of Owen, Better and Hoban (1960) . Low levels were found in some cases of cirrhosis and a small number of patients with obstructive jaundice had raised levels; 70 % of the values, however, fell within the normal range of 8 to 154 mg./IOO mI. (mean = 81·0 mg./l00 mI.). The estimation was of no value in distinguishing between intraand extra-hepatic obstructive jaundice, and did not prove to be as useful a test for the differential diagnosis of parenchymal liver disease and obstructive jaundice as Owen, Padanyi and Smith (1961) have suggested. A characteristic pattern was observed in infective hepatitis, and a falling serum haptoglobin in the presence of increasing jaundice appears to be diagnostic of this condition.
Prednisolone therapy resulted in a rise in serum haptoglobin level in cirrhosis when associated with an improvement in liver function. Temporary rises in haptoglobin level were usually observed in intrahepatic obstructive jaundice (biliary cirrhosis) and were probably due to a non-specific effect of prednisolone; in this condition norethandrolone therapy often caused considerable increases in the serum haptoglobin levels.
